ÂÜÀòÂÒÂ×

Claudia started her career in 1998 in Investment Banking, where she managed M&A projects across various industries for WestLB AG. After completing an international MBA at Instituto de Empresa in Spain, she joined Cellerix SA in 2006, where she contributed to the company’s growth through its series B and C financing rounds, its merger with TiGenix SA and the partnering of its lead asset with Takeda in a licensing deal worth up to €380M. Following the TiGenix’ Nasdaq IPO, Claudia became responsible for investor relations and communications until the Company’s acquisition by Takeda in 2018 in a deal worth >€500M.

From 2019 until Feb 2022 Claudia was the CEO of Algenex SL. Under her leadership, Algenex grew from a university - based R&D site to a GMP-grade CDMO with capacity to manufacture up to 100M vaccine doses per year, a first vaccine approved by EMA and UK regulators and signed commercial agreements with leading companies in the human and animal health space. Algenex was recognized as the best animal health company in Europe in 2021 by IHS (part of S&P global).